ADIL — Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 5
- Website: https://www.adialpharma.com
Latest SEC filings for ADIL
- S-8 — 2026-08-28
- S-3 — 2026-08-28
- 8-K — 2026-05-11
- 10-Q — 2026-05-08
- 8-K — 2026-04-09
- 8-K — 2026-03-06
- 10-K — 2026-03-05
- 8-K — 2026-03-03
- 8-K — 2026-02-24
- 8-K — 2026-02-04
Latest ADIL news
- — Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire Inc.)
Educational tool only — not investment advice.